Latest Insider Transactions at Cortexyme, Inc. (CRTX)
This section provides a real-time view of insider transactions for Cortexyme, Inc. (CRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cortexyme, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cortexyme, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 30
2024
|
Dirk Thye CEO AND CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
77,000
+8.36%
|
$0
$0.7 P/Share
|
|
Aug 29
2024
|
Dirk Thye CEO AND CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
77,500
+9.18%
|
$0
$0.69 P/Share
|
|
Aug 21
2024
|
Brendan Hannah CHIEF BUSINESS OFFICER AND COO |
BUY
Open market or private purchase
|
Direct |
30,845
+3.33%
|
$0
$0.62 P/Share
|
|
Aug 20
2024
|
Charles S. Ryan PRESIDENT |
BUY
Open market or private purchase
|
Direct |
48,387
+28.32%
|
$0
$0.65 P/Share
|
|
Aug 20
2024
|
Brendan Hannah CHIEF BUSINESS OFFICER AND COO |
BUY
Open market or private purchase
|
Direct |
5,924
+1.11%
|
$0
$0.61 P/Share
|
|
Aug 19
2024
|
Brendan Hannah CHIEF BUSINESS OFFICER AND COO |
BUY
Open market or private purchase
|
Direct |
2,155
+0.82%
|
$0
$0.58 P/Share
|
|
Jun 04
2024
|
Brendan Hannah CHIEF BUSINESS OFFICER AND COO |
BUY
Exercise of conversion of derivative security
|
Direct |
56,061
+17.87%
|
$0
$0.55 P/Share
|
|
Jan 16
2024
|
Dirk Thye CEO AND CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
240,530
+16.12%
|
$0
$0.75 P/Share
|
|
Dec 14
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
22,627
+0.95%
|
$22,627
$1.04 P/Share
|
|
Dec 13
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
22,627
+0.96%
|
$22,627
$1.0 P/Share
|
|
Dec 12
2023
|
David Lamond |
BUY
Open market or private purchase
|
Direct |
22,327
+0.96%
|
$22,327
$1.02 P/Share
|
|
Dec 12
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
300
+0.01%
|
$300
$1.0 P/Share
|
|
Dec 07
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
19,123
+0.83%
|
$19,123
$1.01 P/Share
|
|
Dec 06
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
19,123
+0.84%
|
$19,123
$1.02 P/Share
|
|
Dec 05
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
19,123
+0.85%
|
$19,123
$1.01 P/Share
|
|
Dec 01
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
14,378
+0.64%
|
$0
$0.94 P/Share
|
|
Nov 30
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
14,378
+0.65%
|
$0
$0.9 P/Share
|
|
Nov 29
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
14,378
+0.65%
|
$0
$0.98 P/Share
|
|
Aug 31
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
41,026
+1.85%
|
$41,026
$1.32 P/Share
|
|
Aug 30
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
41,026
+1.88%
|
$41,026
$1.31 P/Share
|
|
Aug 17
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
24,766
+1.17%
|
$24,766
$1.29 P/Share
|
|
Aug 16
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
117,348
+5.36%
|
$117,348
$1.29 P/Share
|
|
Aug 15
2023
|
David Lamond |
BUY
Open market or private purchase
|
Indirect |
107,886
+5.23%
|
$107,886
$1.32 P/Share
|
|
Aug 10
2023
|
Dirk Thye CEO AND CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
88,000
+16.39%
|
$88,000
$1.26 P/Share
|
|
Aug 08
2023
|
Brendan Hannah CHIEF BUSINESS OFFICER AND COO |
BUY
Open market or private purchase
|
Direct |
71,762
+26.26%
|
$71,762
$1.22 P/Share
|
|
Aug 08
2023
|
Dirk Thye CEO AND CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
80,000
+18.14%
|
$80,000
$1.24 P/Share
|
|
Aug 08
2023
|
Margaret Mc Loughlin |
BUY
Open market or private purchase
|
Direct |
8,000
+50.0%
|
$8,000
$1.23 P/Share
|
|
Mar 06
2023
|
Ted Monohon Chief Accounting Officer & VP |
SELL
Open market or private sale
|
Direct |
1,871
-6.38%
|
$0
$0.98 P/Share
|
|
Dec 05
2022
|
Ted Monohon Chief Accounting Officer & VP |
SELL
Payment of exercise price or tax liability
|
Direct |
1,640
-5.3%
|
$0
$0.72 P/Share
|
|
Sep 06
2022
|
Ted Monohon Chief Accounting Officer & VP |
SELL
Payment of exercise price or tax liability
|
Direct |
1,520
-4.68%
|
$1,520
$1.64 P/Share
|
|
Jun 06
2022
|
Caryn Gordon Mc Dowell Chief Legal & Adm. Officer |
SELL
Open market or private sale
|
Direct |
10,800
-8.1%
|
$21,600
$2.86 P/Share
|
|
Jun 06
2022
|
Caryn Gordon Mc Dowell Chief Legal & Adm. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,700
-4.79%
|
$13,400
$2.86 P/Share
|
|
Jun 06
2022
|
Leslie Holsinger EVP, Preclinical Development |
SELL
Payment of exercise price or tax liability
|
Direct |
10,920
-6.87%
|
$21,840
$2.86 P/Share
|
|
Jun 06
2022
|
Ted Monohon Chief Accounting Officer & VP |
SELL
Payment of exercise price or tax liability
|
Direct |
1,529
-4.5%
|
$4,587
$3.12 P/Share
|
|
May 19
2022
|
Brendan Hannah CHIEF BUSINESS OFFICER AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
16,224
+50.0%
|
-
|
|
May 19
2022
|
David Lamond |
BUY
Grant, award, or other acquisition
|
Indirect |
200,002
+10.34%
|
-
|
|
May 19
2022
|
Philip S Low Director |
BUY
Grant, award, or other acquisition
|
Indirect |
63,974
+50.0%
|
-
|
|
May 19
2022
|
Philip S Low Director |
BUY
Grant, award, or other acquisition
|
Direct |
455,309
+50.0%
|
-
|
|
May 19
2022
|
Karen L. Smith Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,336
+50.0%
|
-
|
|
May 19
2022
|
Dirk Thye CEO AND CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
64,589
+50.0%
|
-
|
|
Mar 03
2022
|
Michael J. Detke Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,000
+50.0%
|
-
|
|
Mar 03
2022
|
Leslie Holsinger EVP, Preclinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
155,500
+49.44%
|
-
|
|
Mar 03
2022
|
Christopher P. Lowe Interim CEO, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
175,000
+39.77%
|
-
|
|
Mar 03
2022
|
Caryn Gordon Mc Dowell Chief Legal & Adm. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,000
+50.0%
|
-
|
|
Mar 03
2022
|
Ted Monohon Chief Accounting Officer & VP |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+50.0%
|
-
|
|
Nov 18
2021
|
Casey Lynch Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+35.32%
|
$0
$0.46 P/Share
|
|
Nov 16
2021
|
Christopher P. Lowe Interim CEO, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+25.0%
|
$60,000
$2.23 P/Share
|
|
Nov 12
2021
|
Stephen S. Dominy Chief Scientific Officer |
BUY
Open market or private purchase
|
Indirect |
763
+0.06%
|
$10,682
$14.4 P/Share
|
|
Oct 08
2021
|
Margaret Mc Loughlin |
SELL
Open market or private sale
|
Direct |
1,000
-100.0%
|
$88,000
$88.93 P/Share
|
|
Oct 08
2021
|
Margaret Mc Loughlin |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$17,000
$17.0 P/Share
|